USA Health Homepage

Navigation

Rocconi Rodney

Rodney P. Rocconi, M.D., F.A.C.O.G.

Gynecologic OncologistAssociate Director for Clinical Research; Abraham A. Mitchell Clinical Cancer Research Scholar; Professor of Interdisciplinary Clinical OncologySpecialty: Cancer Care
Refer a Patient
Request an Appointment
Or call to make an appointment1 (251) 665-8000

About Rodney P. Rocconi, M.D.

Rodney P. Rocconi, M.D., joined Mitchell Cancer Institute (MCI) as a physician-scientist in the Gynecologic Oncology Service in 2007. He was the first MCI Abraham A. Mitchell Cancer Research Scholar. He specializes in the management of cancers of the ovary, uterus, cervix and lower genital tract. As the Associate Director for Clinical Research, Dr. Rocconi provides leadership and medical expertise to the clinical trials department, reviews and designs clinical research protocols, evaluates safety and efficacy data, analyzes and summarizes data for presentation to regulatory agencies, and provides strategic guidance on non-regulatory clinical trial plans. He is the recipient of the Gynecologic Cancer Foundation Ovarian Cancer Research Award and the Gynecologic Oncology Young Investigator Research Award. Dr. Rocconi also serves as a scientific expert reviewer for the U.S. Department of Defense Ovarian Cancer Research Program.

Conditions Treated

  • Cervical Cancer
  • Endometrial Cancer
  • Ovarian Cancer
  • Uterine Cancer
  • Vulva Cancer

Board Certifications

  • American Board of Obstetrics and Gynecology (Obstetrics and Gynecology)
  • American Board of Obstetrics and Gynecology (Gynecologic Oncology)

Education

  • Medical School: University of Alabama at Birmingham | Birmingham, AL
  • Residency: University of Alabama at Birmingham | Birmingham, AL
  • Fellowship: University of Alabama at Birmingham | Birmingham, AL

Research Interests

  • Management of cancers of the ovary, uterus, cervix and lower genital tract
  • Development of screening tests for ovarian and endometrial cancer

Languages

  • English

Locations

USA Health has a comprehensive biomedical research program that spans a wide range of clinical, basic and translational research.​ At the Mitchell Cancer Institute, our physicians and scientific investigators are searching for breakthrough discoveries to improve the lives of cancer patients.

Clinical Trials

19-004 - Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)Status: open

A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)

Patients with Endometrial Carcinoma

Mitchell Cancer Institute
1660 SpringHill Avenue
Mobile, Alabama 36604
Learn More
(251) 445-9834
19-362 - Safety and Pharmacokinetics Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)Status: open

A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors

Treatment for Advanced Solid Tumors

Mitchell Cancer Institute
1660 SpringHill Avenue
Mobile, Alabama 36604
Learn More
(251) 445-9834
18-325 - A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid TumorsStatus: open


A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors

Treatment for Solid Tumors

Mitchell Cancer Institute
1660 SpringHill Avenue
Mobile, Alabama 36604
Learn More
(251) 445-9834
19-255 - Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical CancerStatus: open

A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (anti–PD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS

Treatment for Cervical Cancer

Mitchell Cancer Institute
1660 SpringHill Avenue
Mobile, Alabama 36604
Learn More
(251) 445-9834
19-446 - A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast CancerStatus: open

A PHASE III, DOUBLE-BLIND,PLACEBO-CONTROLLED, RANDOMIZED STUDY OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND PACLITAXEL AS A TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER

Treatment for Breast Cancer

Mitchell Cancer Institute
1660 SpringHill Avenue
Mobile, Alabama 36604
Learn More
(251) 445-9834
19-077 - Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal CancerStatus: open

A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer.

Treatment for Uterine / Vaginal Cancer

Mitchell Cancer Institute
1660 SpringHill Avenue
Mobile, Alabama 36604
Learn More
(251) 445-9834

Related News

This link will open in a new tab or window.